Allergen-specific immunotherapy.
Allergy is a significant health problem in industrialized countries and its prevalence is continually on the increase: In 1906, when Clemens von Pirquet introduced the term "allergy" to describe overwhelming pathological reactions of the body caused by contact with antigens, less than 1% of the population were affected. Today, more than 25% of the inhabitants of industrialized countries suffer from allergic rhinitis, conjunctivitis, asthma, dermatitis or food allergies. Allergic symptoms can be alleviated using corticosteroids, antihistamines, cromones, decongestants, antimuscarinics or leukotrien antagonists. However, only immunotherapy is able to change the course of allergic disease and to lead to a long-term improvement which is sustained years after the discontinuation of this treatment.
Niederberger
Verena
V
Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria. verena.niederberger@meduniwien.ac.at
D000276:Adjuvants, Immunologic; D000485:Allergens / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D000707:Anaphylaxis / Q000209:etiology / Q000517:prevention & control; D000818:Animals; D003888:Desensitization, Immunologic / Q000009:adverse effects / Q000639:trends; D005818:Genetic Engineering; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000276:immunology* / Q000503:physiopathology / Q000517:prevention & control; D007073:Immunoglobulin E / Q000276:immunology*; D011092:Polyethylene Glycols; D011499:Protein Processing, Post-Translational / Q000276:immunology; D011994:Recombinant Proteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000485:Allergens; D011994:Recombinant Proteins; D007073:Immunoglobulin E; D011092:Polyethylene Glycols